Reports
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States
Americas
Future Market Insights, Inc.
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States
MEA
Future Market Insights
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom
Asia Pacific
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045, India
The antibodies market size is estimated to be worth US$ 236.9 Billion in 2023 and is anticipated to increase at a CAGR of 13.4% from 2023 to 2033. By 2033, it is anticipated that the market for antibodies would reach US$ 834.2 Billion. The total market value of the antibodies sector represented as global market absolute dollar growth is US$ 597.3 Billion.
The impressive growth of the market is likely to be attributed to multiple factors. The rise in demand for antibodies for repeatable research is one of the main factors driving the antibodies market expansion. The market for antibodies is expanding as a result of expanded proteomics and genomics research fields as well as increased research and development efforts in the life sciences industry.
The market for antibodies is also affected by the expansion of industry-academia collaborations, stem cell and neurobiology research, and the desire to address global unmet medical needs.
Attributes | Details |
---|---|
Antibodies market’ HCAGR (2017 to 2022) | 12.4% |
Antibodies market’ CAGR (2023 to 2033) | 13.4% |
Market Size for Antibodies (2023) | US$ 236.9 Billion |
Market Size for Antibodies (2033) | US$ 834.2 Billion |
Market Size for Antibodies’ Absolute Dollar Growth | US$ 597.3 Billion |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Antibodies are essential for treating medical conditions like autoimmune diseases, cancer, and various types of neurological diseases. A certain type of antibody called immunoglobulin (IG) is used for the prevention of lower respiratory tract infections and diseases caused by the vaccinia virus. Rising cases of viral infection are anticipated to drive the demand for antibodies.
National Stem Cell Foundation (NSCF) has reported that about 4% of the global population is affected by some kind of autoimmune disease. The most common autoimmune diseases are diabetes, multiple sclerosis, Crohn’s disease, and rheumatoid arthritis. Autoimmune diseases also act as a host for multiple chronic ailments. As the prevalence of autoimmune diseases is on the rise, the demand for antibodies is forecast to increase in the upcoming years.
In April 2021, Xencor commenced its Phase I clinical trial of its newly engineered Interleukin-2 (IL-2) Fc cytokine and XmAb564 antibody therapeutics designed for developing the treatment of patients with autoimmune diseases. Novel biosimilar antibody manufacturers are slashing their prices to compete with branded antibody manufacturers, especially in the European market. With the expiration of patents of renowned products, a boost in demand for biosimilar antibodies can be expected in upcoming years.
How do Research and Development Activities Impact Antibodies Sales Outlook?
A surge in research and development activities among pharmaceutical market leaders to develop economical and effective antibodies and biosimilar antibodies is driving growth opportunities for the antibodies market.
In February 2021, Abingdon Health collaborated with Abcam to explore opportunities for their service and portfolio expansion which includes Abcam's reagent portfolio and Abingdon Health's rapid test contract development and manufacturing services.
Rising cases of multiple sclerosis and Parkinson's disease among the older population is a key factor fueling the demand for antibodies. There is an urgency to develop personalized and cheap medicines, advanced therapeutics, advanced genetic engineering technology, and novel and effective treatments in middle-income countries. This is expected to positively influence the sales of antibodies.
In 2021, Berkeley Lights, a digital cell biology company, joined hands with Genovac, an antibody discovery company, to readily access the right antibodies in the shortest amount of time with the help of modern technology.
Considering this, the rising application of antibodies in chronic disease treatment is anticipated to create scope for antibodies market expansion in the near future.
How is Increasing Production of Bio-similar Antibodies driving Demand?
Biosimilar antibodies are experiencing heavy demand as they are inexpensive in comparison with human monoclonal antibodies, and they have very few side effects. In 2020, Johnson and Johnson reported US$ 3.75 Billion achieved through the sales of Remicade. According to Pfizer, Inflectra, the biosimilar competitor of Remicade, generated US$ 659 Million in 2020.
USA Food and Drug Administration (FDA) approved a biosimilar of Remicade called Avsola in December 2019 and is now eligible for producing biologics products all over the world. Increasing demand for biosimilar antibodies in the treatment of rheumatoid arthritis, along with a high patient acceptance rate, is anticipated to boost the market growth for antibodies.
One of the leaders in prescription medicines, Pfizer, received EU approval for biosimilar antibody therapeutics Amsparity for Crohn’s disease, psoriasis, and psoriatic arthritis in February 2020. Elevated new drug approval rates and products in clinical trials in pharmaceutical companies are anticipated to drive the market in the upcoming years.
Antibodies Market:
Attributes | Antibodies Market |
---|---|
CAGR (2023 to 2033) | 13.4% |
Market Value (2023) | US$ 236.9 Billion |
Growth Factor | Strong investments in medical research and development are anticipated to fuel antibodies’ prospective growth. |
Opportunity | Low regulatory requirements make it a desirable option for antibody businesses and increase market potential exceptionally quickly. |
Key Trends | Growing Healthcare Industry Research Increases Demand for Antibody Production |
Antibody Fragments Market:
Attributes | Antibody Fragments Market |
---|---|
CAGR (2023 to 2033) | 5.9% |
Market Value (2023) | USD 8.01 Billion |
Growth Factor | Infectious and chronic diseases are becoming more common. |
Opportunity | The growing geriatric population in developing economies is anticipated to boost industrial demand in the coming years. |
Key Trends | Antibody Fragments Preferentially Over Alternatives |
Antibody Production Market:
Attributes | Antibody Production Market |
---|---|
CAGR (2023 to 2033) | 13.5% |
Market Value (2023) | USD 17.96 Billion |
Growth Factor | A major factor driving growth is the increasing focus of biopharmaceutical and biotechnology companies on the production of antibody therapeutics. |
Opportunity | A focus on Research and Development is an essential strategy for driving the company's long-term growth. |
Key Trends | The production of therapeutic antibodies is increasing, which is anticipated to drive market growth during the forecast period. |
Country | USA |
---|---|
CAGR (2023 to 2033) | 14.1% |
HCAGR (2017 to 2022) | 13.6% |
Country | United Kingdom |
---|---|
CAGR (2023 to 2033) | 15.9% |
HCAGR (2017 to 2022) | 15.0% |
Country | Germany |
---|---|
CAGR (2023 to 2033) | 14.5% |
HCAGR (2017 to 2022) | 14.2% |
Country | China |
---|---|
CAGR (2023 to 2033) | 13.6% |
HCAGR (2017 to 2022) | 11.4% |
Country | India |
---|---|
CAGR (2023 to 2033) | 13.6% |
HCAGR (2017 to 2022) | 12.3% |
The USA is the leading manufacturer of antibodies owing to modern healthcare infrastructural facilities and the presence of leading market players in the country. The increasing purchasing power of consumers, along with increasing government funding, is anticipated to drive the growth opportunities for the antibodies market, along with the emerging markets for the antibodies sector.
Attributes | Details |
---|---|
USA Market Size (2033) | US$ 368.9 Billion |
USA Market Absolute Dollar Growth (US$ Million/Billion) | US$ 270.2 Billion |
National Health Accounts by Centers for Medicare & Medicaid Services (CMS) in its report states that healthcare spending in the USA grew by around 4.6% in 2019. Rising cases of cancer and autoimmune diseases in the country are anticipated to further increase the demand for antibodies.
National Stem Cell Foundation (NSCF) states that autoimmune diseases are the third most common reason for chronic ailments in the USA Increasing cases of diabetes and multiple sclerosis in the country are anticipated to positively influence the demand for antibodies.
Attributes | Details |
---|---|
United Kingdom Market Size (2033) | US$ 42.5 Billion |
United Kingdom Market Absolute Dollar Growth (US$ Million/Billion) | US$ 32.8 Billion |
Due to the increased prevalence of malignancies, cardiovascular illnesses, autoimmune diseases, and high spending on antibody Research and Development, the United Kingdom for antibodies is also anticipated to account for a sizeable portion of global sales of antibodies.
In addition to this, high investments made by the government towards keeping up the health of their citizens are directing the market towards advancement.
Attributes | Details |
---|---|
Germany Market Size (2033) | US$ 32.5 Billion |
Germany Market Absolute Dollar Growth (US$ Million/Billion) | US$ 24.1 Billion |
Germany's antibody market has grown as a result of some of the top companies in the nation's sector, whose products are in great demand. The market is anticipated to see a profit from disease prevalence as well as Germany's high treatment spending capacity on cutting-edge medicines.
The market size for antibodies is anticipated to be impacted by ongoing technological developments, more accessibility, and increased disposable income.
Attributes | Details |
---|---|
China Market Size (2033) | US$ 35.6 Billion |
China Market Absolute Dollar Growth (US$ Million/Billion) | US$ 25.7 Billion |
World Bank evaluated that healthcare expenditure in China accounted for 5.35% of its gross domestic product (GDP) in 2018. The rising geriatric population and associated ailments are anticipated to drive market growth for antibodies in the upcoming years.
Development and production of antibodies in China are expected to increase significantly owing to increasing government investment towards drug development coupled with growing awareness about various medical ailments like rheumatoid arthritis, cancer, and infections. China developed its first USA Food and Drug Administration (FDA) approved antibody in March 2018. The antibody named Trogarzo was useful in treating resistant HIV infections. Similarly, more than ten other China-made biologics are under clinical trials.
The government also started a Chinese Antibody Society with the aim of assisting in speedy FDA approval as well as ensuring effective marketing of China-made antibody-based therapeutics. These initiatives are expected to reflect positively on the China market, presenting a conducive environment for the growth in sales of antibodies.
Attributes | Details |
---|---|
India Market Size (2033) | US$ 30.3 Billion |
India Market Absolute Dollar Growth (US$ Million/Billion) | US$ 21.9 Billion |
Indian antibodies market is anticipated to grow at a rapid pace owing to rising cases of cancer and cardiovascular diseases along with the development of the healthcare system in the country.
As per the data from Global Cancer Observatory, 1.322 million new cancer cases were registered in India in 2020, while 2.72 million people had cancer for 5 years. A surge in cancer patients is anticipated to drive the demand for antibodies for cancer treatment.
Rapid technological advancements, increasing government funding to make the treatment affordable, and increasing consumer spending on healthcare are anticipated to create opportunities for antibodies market growth in India.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Top Disease Indication | Cancer |
---|---|
HCAGR (2017 to 2022) | 13.4% |
CAGR (2023 to 2033) | 14.8% |
The rising prevalence of non-Hodgkin lymphoma and other types of cancer has fuelled the demand for cancer antibodies for developing non-invasive and safe treatment options. With the focus on cancer research increasing, the antibodies market outlook for the upcoming decade is anticipated to remain positive.
According to disease indications, the cancer sector is the largest shareholder in the antibodies market, owing to increased cancer prevalence and increased adoption of antibodies in cancer treatment. An increase in the number of drug pipelines, an increase in demand for biosimilar monoclonal antibodies, and an increase in patient awareness of cancer treatment methods boost market expansion.
The rising prevalence of non-Hodgkin lymphoma and other types of cancer has fuelled the demand for cancer antibodies for developing noninvasive and safe treatment options. With the focus on cancer research increasing, the antibodies market outlook for the upcoming decade is anticipated to remain positive.
Top Product Type | Monoclonal Antibodies |
---|---|
HCAGR (2017 to 2022) | 12.4% |
CAGR (2023 to 2033) | 13.6% |
Monoclonal antibodies are predicted to showcase elevated demand throughout the forecast period owing to rising drug approval rates. Besides this, sales in this category are anticipated to rise in response to the increasing cases of rheumatoid arthritis, psoriasis, and asthma in the geriatric population across the globe.
The rising demand for effective treatment of aforementioned chronic ailments is anticipated to remain a chief growth driver in this category for the antibodies market.
Hospitals are expected to generate the highest demand throughout the forecast period. A growing pool of patients and faster accessibility to healthcare is anticipated to elevate the demand in Hospitals.
Hospitals around the world register a higher footfall of patients as they offer expert care and the infrastructure required for administering the necessary treatment. The demand for antibodies in hospitals multiplied amid the pandemic. Even as governments roll out vaccination drives to contain the pandemic, hospitals are anticipated to remain the dominant end-user on account of rising cases of various types of chronic ailments.
Startups Should Concentrate on Increasing the Scope of Their Research to Promote Innovation.
Future market players should concentrate on acquiring additional money through financing rounds to broaden their research and company scope. New businesses are looking into how to leverage cutting-edge technologies to streamline the creation of therapeutic antibodies, including nanobodies and monoclonal antibodies.
Reputable market giants are starting new collaborations and projects that may help emerging markets for the antibodies sector succeed in the very competitive antibodies market.
Future Market Insights (FMI) has found that market players are working towards developing new antibodies to treat cancer and other diseases. They are also researching to create long-acting antibody drugs to reduce healthcare costs.
In order to gain a competitive edge in the antibodies market, key players are developing oral and noninvasive treatments using antibodies to treat chronic ailments. Strategic mergers and acquisitions for portfolio expansion are in the cards as well.
Recent Development:
On June 11, 2021, Novartis published its new Phase II data of an investigational oral treatment iptacopan, developed for treating paroxysmal nocturnal hemoglobinuria (PNH). The study indicated that during 12 weeks of iptacopan monotherapy treatment, no unexpected safety issues were reported which led to rapid and durable transfusion-free improvement of hemoglobin levels in the majority of patients.
In August 2020, Johnson & Johnson entered into a final agreement to acquire Momenta Pharmaceuticals Inc. for around US$ 6.5 Billion. Momenta Pharmaceuticals Inc. is a market leader in developing novel therapies for immune-mediated diseases.
The acquisition may allow the Janssen Pharmaceutical Companies of Johnson & Johnson to expand its product portfolio in immune-mediated diseases while driving growth opportunities for the antibodies market through expansion into autoantibody-driven disease.
Leading pharmaceutical company Sanofi announced in March 2022 that it will collaborate with IGM Biosciences to research, produce, and market six novel immunoglobulin M antibody agonists. Sanofi has agreed to approximately US$ 6 billion in possible milestone payments through this agreement.
1. Executive Summary | Antibodies Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity ; 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2017 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2017 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Disease Indication 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Disease Indication, 2017 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Disease Indication, 2023 to 2033 5.3.1. Cardiovascular Diseases 5.3.2. CNS Disorders 5.3.3. Cancer 5.3.4. Autoimmune Disorders 5.4. Y-o-Y Growth Trend Analysis By Disease Indication, 2017 to 2022 5.5. Absolute $ Opportunity Analysis By Disease Indication, 2023 to 2033 6. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Product Type 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Product Type, 2017 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Product Type, 2023 to 2033 6.3.1. Monoclonal 6.3.2. Polyclonal 6.3.3. Antibody-drug Complexes 6.4. Y-o-Y Growth Trend Analysis By Product Type, 2017 to 2022 6.5. Absolute $ Opportunity Analysis By Product Type, 2023 to 2033 7. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By End User 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By End User, 2017 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033 7.3.1. Hospitals 7.3.2. Long-term Care Facilities 7.3.3. Research Institutes 7.4. Y-o-Y Growth Trend Analysis By End User, 2017 to 2022 7.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033 8. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2017 to 2022 8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 8.3.1. North America 8.3.2. Latin America 8.3.3. Western Europe 8.3.4. Eastern Europe 8.3.5. Asia Pacific Excluding Japan 8.3.6. Japan 8.3.7. Middle East and Africa(MEA) 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. USA 9.2.1.2. Canada 9.2.2. By Disease Indication 9.2.3. By Product Type 9.2.4. By End User 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Disease Indication 9.3.3. By Product Type 9.3.4. By End User 9.4. Key Takeaways 10. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Argentina 10.2.1.2. Brazil 10.2.1.3. Mexico 10.2.1.4. Rest of Latin America 10.2.2. By Disease Indication 10.2.3. By Product Type 10.2.4. By End User 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Disease Indication 10.3.3. By Product Type 10.3.4. By End User 10.4. Key Takeaways 11. Western Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. United Kingdom 11.2.1.2. Germany 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Nordic 11.2.1.7. Benelux 11.2.1.8. Rest of Western Europe 11.2.2. By Disease Indication 11.2.3. By Product Type 11.2.4. By End User 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Disease Indication 11.3.3. By Product Type 11.3.4. By End User 11.4. Key Takeaways 12. Eastern Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. Russia 12.2.1.2. Poland 12.2.1.3. Rest of Eastern Europe 12.2.2. By Disease Indication 12.2.3. By Product Type 12.2.4. By End User 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Disease Indication 12.3.3. By Product Type 12.3.4. By End User 12.4. Key Takeaways 13. APEJ Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. China 13.2.1.2. India 13.2.1.3. ASEAN 13.2.1.4. Australia & New Zealand 13.2.1.5. Rest of Asia Pacific Excluding Japan 13.2.2. By Disease Indication 13.2.3. By Product Type 13.2.4. By End User 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Disease Indication 13.3.3. By Product Type 13.3.4. By End User 13.4. Key Takeaways 14. Japan Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.2. By Disease Indication 14.2.3. By Product Type 14.2.4. By End User 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Disease Indication 14.3.3. By Product Type 14.3.4. By End User 14.4. Key Takeaways 15. MEA Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. GCC Countries 15.2.1.2. South Africa 15.2.1.3. North Africa 15.2.1.4. Rest of Middle East and Africa(MEA) 15.2.2. By Disease Indication 15.2.3. By Product Type 15.2.4. By End User 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Disease Indication 15.3.3. By Product Type 15.3.4. By End User 15.4. Key Takeaways 16. Key Countries Market Analysis 16.1. USA 16.1.1. Pricing Analysis 16.1.2. Market Share Analysis, 2022 16.1.2.1. By Disease Indication 16.1.2.2. By Product Type 16.1.2.3. By End User 16.2. Canada 16.2.1. Pricing Analysis 16.2.2. Market Share Analysis, 2022 16.2.2.1. By Disease Indication 16.2.2.2. By Product Type 16.2.2.3. By End User 16.3. Argentina 16.3.1. Pricing Analysis 16.3.2. Market Share Analysis, 2022 16.3.2.1. By Disease Indication 16.3.2.2. By Product Type 16.3.2.3. By End User 16.4. Brazil 16.4.1. Pricing Analysis 16.4.2. Market Share Analysis, 2022 16.4.2.1. By Disease Indication 16.4.2.2. By Product Type 16.4.2.3. By End User 16.5. Mexico 16.5.1. Pricing Analysis 16.5.2. Market Share Analysis, 2022 16.5.2.1. By Disease Indication 16.5.2.2. By Product Type 16.5.2.3. By End User 16.6. United Kingdom 16.6.1. Pricing Analysis 16.6.2. Market Share Analysis, 2022 16.6.2.1. By Disease Indication 16.6.2.2. By Product Type 16.6.2.3. By End User 16.7. Germany 16.7.1. Pricing Analysis 16.7.2. Market Share Analysis, 2022 16.7.2.1. By Disease Indication 16.7.2.2. By Product Type 16.7.2.3. By End User& 16.8. France 16.8.1. Pricing Analysis 16.8.2. Market Share Analysis, 2022 16.8.2.1. By Disease Indication 16.8.2.2. By Product Type 16.8.2.3. By End User 16.9. Spain 16.9.1. Pricing Analysis 16.9.2. Market Share Analysis, 2022 16.9.2.1. By Disease Indication 16.9.2.2. By Product Type 16.9.2.3. By End User 16.10. Italy 16.10.1. Pricing Analysis 16.10.2. Market Share Analysis, 2022 16.10.2.1. By Disease Indication 16.10.2.2. By Product Type 16.10.2.3. By End User 16.11. Nordic 16.11.1. Pricing Analysis 16.11.2. Market Share Analysis, 2022 16.11.2.1. By Disease Indication 16.11.2.2. By Product Type 16.11.2.3. By End User 16.12. Benelux 16.12.1. Pricing Analysis 16.12.2. Market Share Analysis, 2022 16.12.2.1. By Disease Indication 16.12.2.2. By Product Type 16.12.2.3. By End User 16.13. Russia 16.13.1. Pricing Analysis 16.13.2. Market Share Analysis, 2022 16.13.2.1. By Disease Indication 16.13.2.2. By Product Type 16.13.2.3. By End User 16.14. Poland 16.14.1. Pricing Analysis 16.14.2. Market Share Analysis, 2022 16.14.2.1. By Disease Indication 16.14.2.2. By Product Type 16.14.2.3. By End User 16.15. China 16.15.1. Pricing Analysis 16.15.2. Market Share Analysis, 2022 16.15.2.1. By Disease Indication 16.15.2.2. By Product Type 16.15.2.3. By End User 16.16. India 16.16.1. Pricing Analysis 16.16.2. Market Share Analysis, 2022 16.16.2.1. By Disease Indication 16.16.2.2. By Product Type 16.16.2.3. By End User 16.17. ASEAN 16.17.1. Pricing Analysis 16.17.2. Market Share Analysis, 2022 16.17.2.1. By Disease Indication 16.17.2.2. By Product Type 16.17.2.3. By End User 16.18. Australia & New Zealand 16.18.1. Pricing Analysis 16.18.2. Market Share Analysis, 2022 16.18.2.1. By Disease Indication 16.18.2.2. By Product Type 16.18.2.3. By End User 16.19. Japan 16.19.1. Pricing Analysis 16.19.2. Market Share Analysis, 2022 16.19.2.1. By Disease Indication 16.19.2.2. By Product Type 16.19.2.3. By End User 16.20. GCC Countries 16.20.1. Pricing Analysis 16.20.2. Market Share Analysis, 2022 16.20.2.1. By Disease Indication 16.20.2.2. By Product Type 16.20.2.3. By End User 16.21. South Africa 16.21.1. Pricing Analysis 16.21.2. Market Share Analysis, 2022 16.21.2.1. By Disease Indication 16.21.2.2. By Product Type 16.21.2.3. By End User 17. Market Structure Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Market Share Analysis of Top Players 17.3.1. By Regional 17.3.2. By Disease Indication 17.3.3. By Product Type 17.3.4. By End User 18. Competition Analysis 18.1. Competition Deep Dive 18.1.1. Novartis AG 18.1.1.1. Overview 18.1.1.2. Product Portfolio 18.1.1.3. Profitability by Market Segments 18.1.1.4. Sales Footprint 18.1.1.5. Strategy Overview 18.1.1.5.1. Marketing Strategy 18.1.2. F. Hoffmann-La Roche AG 18.1.2.1. Overview 18.1.2.2. Product Portfolio 18.1.2.3. Profitability by Market Segments 18.1.2.4. Sales Footprint 18.1.2.5. Strategy Overview 18.1.2.5.1. Marketing Strategy 18.1.3. Johnson & Johnson 18.1.3.1. Overview 18.1.3.2. Product Portfolio 18.1.3.3. Profitability by Market Segments 18.1.3.4. Sales Footprint 18.1.3.5. Strategy Overview 18.1.3.5.1. Marketing Strategy 18.1.4. Takeda Pharmaceutical Company Limited 18.1.4.1. Overview 18.1.4.2. Product Portfolio 18.1.4.3. Profitability by Market Segments 18.1.4.4. Sales Footprint 18.1.4.5. Strategy Overview 18.1.4.5.1. Marketing Strategy 18.1.5. Amgen Inc. 18.1.5.1. Overview 18.1.5.2. Product Portfolio 18.1.5.3. Profitability by Market Segments 18.1.5.4. Sales Footprint 18.1.5.5. Strategy Overview 18.1.5.5.1. Marketing Strategy 18.1.6. Biogen Inc. 18.1.6.1. Overview 18.1.6.2. Product Portfolio 18.1.6.3. Profitability by Market Segments 18.1.6.4. Sales Footprint 18.1.6.5. Strategy Overview 18.1.6.5.1. Marketing Strategy 18.1.7. Bristol-Myers Squibb Company 18.1.7.1. Overview 18.1.7.2. Product Portfolio 18.1.7.3. Profitability by Market Segments 18.1.7.4. Sales Footprint 18.1.7.5. Strategy Overview 18.1.7.5.1. Marketing Strategy 18.1.8. AbbVie Inc. 18.1.8.1. Overview 18.1.8.2. Product Portfolio 18.1.8.3. Profitability by Market Segments 18.1.8.4. Sales Footprint 18.1.8.5. Strategy Overview 18.1.8.5.1. Marketing Strategy 18.1.9. Sanofi SA 18.1.9.1. Overview 18.1.9.2. Product Portfolio 18.1.9.3. Profitability by Market Segments 18.1.9.4. Sales Footprint 18.1.9.5. Strategy Overview 18.1.9.5.1. Marketing Strategy 18.1.10. Eli Lilly and Co. 18.1.10.1. Overview 18.1.10.2. Product Portfolio 18.1.10.3. Profitability by Market Segments 18.1.10.4. Sales Footprint 18.1.10.5. Strategy Overview 18.1.10.5.1. Marketing Strategy 19. Assumptions & Acronyms Used 20. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Table 1: Global Market Value (US$ Million) Forecast by Region, 2017 to 2033 Table 2: Global Market Value (US$ Million) Forecast by Disease Indication, 2017 to 2033 Table 3: Global Market Value (US$ Million) Forecast by Product Type, 2017 to 2033 Table 4: Global Market Value (US$ Million) Forecast by End User, 2017 to 2033 Table 5: North America Market Value (US$ Million) Forecast by Country, 2017 to 2033 Table 6: North America Market Value (US$ Million) Forecast by Disease Indication, 2017 to 2033 Table 7: North America Market Value (US$ Million) Forecast by Product Type, 2017 to 2033 Table 8: North America Market Value (US$ Million) Forecast by End User, 2017 to 2033 Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2017 to 2033 Table 10: Latin America Market Value (US$ Million) Forecast by Disease Indication, 2017 to 2033 Table 11: Latin America Market Value (US$ Million) Forecast by Product Type, 2017 to 2033 Table 12: Latin America Market Value (US$ Million) Forecast by End User, 2017 to 2033 Table 13: Western Europe Market Value (US$ Million) Forecast by Country, 2017 to 2033 Table 14: Western Europe Market Value (US$ Million) Forecast by Disease Indication, 2017 to 2033 Table 15: Western Europe Market Value (US$ Million) Forecast by Product Type, 2017 to 2033 Table 16: Western Europe Market Value (US$ Million) Forecast by End User, 2017 to 2033 Table 17: Eastern Europe Market Value (US$ Million) Forecast by Country, 2017 to 2033 Table 18: Eastern Europe Market Value (US$ Million) Forecast by Disease Indication, 2017 to 2033 Table 19: Eastern Europe Market Value (US$ Million) Forecast by Product Type, 2017 to 2033 Table 20: Eastern Europe Market Value (US$ Million) Forecast by End User, 2017 to 2033 Table 21: APEJ Market Value (US$ Million) Forecast by Country, 2017 to 2033 Table 22: APEJ Market Value (US$ Million) Forecast by Disease Indication, 2017 to 2033 Table 23: APEJ Market Value (US$ Million) Forecast by Product Type, 2017 to 2033 Table 24: APEJ Market Value (US$ Million) Forecast by End User, 2017 to 2033 Table 25: Japan Market Value (US$ Million) Forecast by Country, 2017 to 2033 Table 26: Japan Market Value (US$ Million) Forecast by Disease Indication, 2017 to 2033 Table 27: Japan Market Value (US$ Million) Forecast by Product Type, 2017 to 2033 Table 28: Japan Market Value (US$ Million) Forecast by End User, 2017 to 2033 Table 29: MEA Market Value (US$ Million) Forecast by Country, 2017 to 2033 Table 30: MEA Market Value (US$ Million) Forecast by Disease Indication, 2017 to 2033 Table 31: MEA Market Value (US$ Million) Forecast by Product Type, 2017 to 2033 Table 32: MEA Market Value (US$ Million) Forecast by End User, 2017 to 2033
Figure 1: Global Market Value (US$ Million) by Disease Indication, 2023 to 2033 Figure 2: Global Market Value (US$ Million) by Product Type, 2023 to 2033 Figure 3: Global Market Value (US$ Million) by End User, 2023 to 2033 Figure 4: Global Market Value (US$ Million) by Region, 2023 to 2033 Figure 5: Global Market Value (US$ Million) Analysis by Region, 2017 to 2033 Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033 Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033 Figure 8: Global Market Value (US$ Million) Analysis by Disease Indication, 2017 to 2033 Figure 9: Global Market Value Share (%) and BPS Analysis by Disease Indication, 2023 to 2033 Figure 10: Global Market Y-o-Y Growth (%) Projections by Disease Indication, 2023 to 2033 Figure 11: Global Market Value (US$ Million) Analysis by Product Type, 2017 to 2033 Figure 12: Global Market Value Share (%) and BPS Analysis by Product Type, 2023 to 2033 Figure 13: Global Market Y-o-Y Growth (%) Projections by Product Type, 2023 to 2033 Figure 14: Global Market Value (US$ Million) Analysis by End User, 2017 to 2033 Figure 15: Global Market Value Share (%) and BPS Analysis by End User, 2023 to 2033 Figure 16: Global Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033 Figure 17: Global Market Attractiveness by Disease Indication, 2023 to 2033 Figure 18: Global Market Attractiveness by Product Type, 2023 to 2033 Figure 19: Global Market Attractiveness by End User, 2023 to 2033 Figure 20: Global Market Attractiveness by Region, 2023 to 2033 Figure 21: North America Market Value (US$ Million) by Disease Indication, 2023 to 2033 Figure 22: North America Market Value (US$ Million) by Product Type, 2023 to 2033 Figure 23: North America Market Value (US$ Million) by End User, 2023 to 2033 Figure 24: North America Market Value (US$ Million) by Country, 2023 to 2033 Figure 25: North America Market Value (US$ Million) Analysis by Country, 2017 to 2033 Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 28: North America Market Value (US$ Million) Analysis by Disease Indication, 2017 to 2033 Figure 29: North America Market Value Share (%) and BPS Analysis by Disease Indication, 2023 to 2033 Figure 30: North America Market Y-o-Y Growth (%) Projections by Disease Indication, 2023 to 2033 Figure 31: North America Market Value (US$ Million) Analysis by Product Type, 2017 to 2033 Figure 32: North America Market Value Share (%) and BPS Analysis by Product Type, 2023 to 2033 Figure 33: North America Market Y-o-Y Growth (%) Projections by Product Type, 2023 to 2033 Figure 34: North America Market Value (US$ Million) Analysis by End User, 2017 to 2033 Figure 35: North America Market Value Share (%) and BPS Analysis by End User, 2023 to 2033 Figure 36: North America Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033 Figure 37: North America Market Attractiveness by Disease Indication, 2023 to 2033 Figure 38: North America Market Attractiveness by Product Type, 2023 to 2033 Figure 39: North America Market Attractiveness by End User, 2023 to 2033 Figure 40: North America Market Attractiveness by Country, 2023 to 2033 Figure 41: Latin America Market Value (US$ Million) by Disease Indication, 2023 to 2033 Figure 42: Latin America Market Value (US$ Million) by Product Type, 2023 to 2033 Figure 43: Latin America Market Value (US$ Million) by End User, 2023 to 2033 Figure 44: Latin America Market Value (US$ Million) by Country, 2023 to 2033 Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2017 to 2033 Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 48: Latin America Market Value (US$ Million) Analysis by Disease Indication, 2017 to 2033 Figure 49: Latin America Market Value Share (%) and BPS Analysis by Disease Indication, 2023 to 2033 Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Disease Indication, 2023 to 2033 Figure 51: Latin America Market Value (US$ Million) Analysis by Product Type, 2017 to 2033 Figure 52: Latin America Market Value Share (%) and BPS Analysis by Product Type, 2023 to 2033 Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Product Type, 2023 to 2033 Figure 54: Latin America Market Value (US$ Million) Analysis by End User, 2017 to 2033 Figure 55: Latin America Market Value Share (%) and BPS Analysis by End User, 2023 to 2033 Figure 56: Latin America Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033 Figure 57: Latin America Market Attractiveness by Disease Indication, 2023 to 2033 Figure 58: Latin America Market Attractiveness by Product Type, 2023 to 2033 Figure 59: Latin America Market Attractiveness by End User, 2023 to 2033 Figure 60: Latin America Market Attractiveness by Country, 2023 to 2033 Figure 61: Western Europe Market Value (US$ Million) by Disease Indication, 2023 to 2033 Figure 62: Western Europe Market Value (US$ Million) by Product Type, 2023 to 2033 Figure 63: Western Europe Market Value (US$ Million) by End User, 2023 to 2033 Figure 64: Western Europe Market Value (US$ Million) by Country, 2023 to 2033 Figure 65: Western Europe Market Value (US$ Million) Analysis by Country, 2017 to 2033 Figure 66: Western Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 67: Western Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 68: Western Europe Market Value (US$ Million) Analysis by Disease Indication, 2017 to 2033 Figure 69: Western Europe Market Value Share (%) and BPS Analysis by Disease Indication, 2023 to 2033 Figure 70: Western Europe Market Y-o-Y Growth (%) Projections by Disease Indication, 2023 to 2033 Figure 71: Western Europe Market Value (US$ Million) Analysis by Product Type, 2017 to 2033 Figure 72: Western Europe Market Value Share (%) and BPS Analysis by Product Type, 2023 to 2033 Figure 73: Western Europe Market Y-o-Y Growth (%) Projections by Product Type, 2023 to 2033 Figure 74: Western Europe Market Value (US$ Million) Analysis by End User, 2017 to 2033 Figure 75: Western Europe Market Value Share (%) and BPS Analysis by End User, 2023 to 2033 Figure 76: Western Europe Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033 Figure 77: Western Europe Market Attractiveness by Disease Indication, 2023 to 2033 Figure 78: Western Europe Market Attractiveness by Product Type, 2023 to 2033 Figure 79: Western Europe Market Attractiveness by End User, 2023 to 2033 Figure 80: Western Europe Market Attractiveness by Country, 2023 to 2033 Figure 81: Eastern Europe Market Value (US$ Million) by Disease Indication, 2023 to 2033 Figure 82: Eastern Europe Market Value (US$ Million) by Product Type, 2023 to 2033 Figure 83: Eastern Europe Market Value (US$ Million) by End User, 2023 to 2033 Figure 84: Eastern Europe Market Value (US$ Million) by Country, 2023 to 2033 Figure 85: Eastern Europe Market Value (US$ Million) Analysis by Country, 2017 to 2033 Figure 86: Eastern Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 87: Eastern Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 88: Eastern Europe Market Value (US$ Million) Analysis by Disease Indication, 2017 to 2033 Figure 89: Eastern Europe Market Value Share (%) and BPS Analysis by Disease Indication, 2023 to 2033 Figure 90: Eastern Europe Market Y-o-Y Growth (%) Projections by Disease Indication, 2023 to 2033 Figure 91: Eastern Europe Market Value (US$ Million) Analysis by Product Type, 2017 to 2033 Figure 92: Eastern Europe Market Value Share (%) and BPS Analysis by Product Type, 2023 to 2033 Figure 93: Eastern Europe Market Y-o-Y Growth (%) Projections by Product Type, 2023 to 2033 Figure 94: Eastern Europe Market Value (US$ Million) Analysis by End User, 2017 to 2033 Figure 95: Eastern Europe Market Value Share (%) and BPS Analysis by End User, 2023 to 2033 Figure 96: Eastern Europe Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033 Figure 97: Eastern Europe Market Attractiveness by Disease Indication, 2023 to 2033 Figure 98: Eastern Europe Market Attractiveness by Product Type, 2023 to 2033 Figure 99: Eastern Europe Market Attractiveness by End User, 2023 to 2033 Figure 100: Eastern Europe Market Attractiveness by Country, 2023 to 2033 Figure 101: APEJ Market Value (US$ Million) by Disease Indication, 2023 to 2033 Figure 102: APEJ Market Value (US$ Million) by Product Type, 2023 to 2033 Figure 103: APEJ Market Value (US$ Million) by End User, 2023 to 2033 Figure 104: APEJ Market Value (US$ Million) by Country, 2023 to 2033 Figure 105: APEJ Market Value (US$ Million) Analysis by Country, 2017 to 2033 Figure 106: APEJ Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 107: APEJ Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 108: APEJ Market Value (US$ Million) Analysis by Disease Indication, 2017 to 2033 Figure 109: APEJ Market Value Share (%) and BPS Analysis by Disease Indication, 2023 to 2033 Figure 110: APEJ Market Y-o-Y Growth (%) Projections by Disease Indication, 2023 to 2033 Figure 111: APEJ Market Value (US$ Million) Analysis by Product Type, 2017 to 2033 Figure 112: APEJ Market Value Share (%) and BPS Analysis by Product Type, 2023 to 2033 Figure 113: APEJ Market Y-o-Y Growth (%) Projections by Product Type, 2023 to 2033 Figure 114: APEJ Market Value (US$ Million) Analysis by End User, 2017 to 2033 Figure 115: APEJ Market Value Share (%) and BPS Analysis by End User, 2023 to 2033 Figure 116: APEJ Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033 Figure 117: APEJ Market Attractiveness by Disease Indication, 2023 to 2033 Figure 118: APEJ Market Attractiveness by Product Type, 2023 to 2033 Figure 119: APEJ Market Attractiveness by End User, 2023 to 2033 Figure 120: APEJ Market Attractiveness by Country, 2023 to 2033 Figure 121: Japan Market Value (US$ Million) by Disease Indication, 2023 to 2033 Figure 122: Japan Market Value (US$ Million) by Product Type, 2023 to 2033 Figure 123: Japan Market Value (US$ Million) by End User, 2023 to 2033 Figure 124: Japan Market Value (US$ Million) by Country, 2023 to 2033 Figure 125: Japan Market Value (US$ Million) Analysis by Country, 2017 to 2033 Figure 126: Japan Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 127: Japan Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 128: Japan Market Value (US$ Million) Analysis by Disease Indication, 2017 to 2033 Figure 129: Japan Market Value Share (%) and BPS Analysis by Disease Indication, 2023 to 2033 Figure 130: Japan Market Y-o-Y Growth (%) Projections by Disease Indication, 2023 to 2033 Figure 131: Japan Market Value (US$ Million) Analysis by Product Type, 2017 to 2033 Figure 132: Japan Market Value Share (%) and BPS Analysis by Product Type, 2023 to 2033 Figure 133: Japan Market Y-o-Y Growth (%) Projections by Product Type, 2023 to 2033 Figure 134: Japan Market Value (US$ Million) Analysis by End User, 2017 to 2033 Figure 135: Japan Market Value Share (%) and BPS Analysis by End User, 2023 to 2033 Figure 136: Japan Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033 Figure 137: Japan Market Attractiveness by Disease Indication, 2023 to 2033 Figure 138: Japan Market Attractiveness by Product Type, 2023 to 2033 Figure 139: Japan Market Attractiveness by End User, 2023 to 2033 Figure 140: Japan Market Attractiveness by Country, 2023 to 2033 Figure 141: MEA Market Value (US$ Million) by Disease Indication, 2023 to 2033 Figure 142: MEA Market Value (US$ Million) by Product Type, 2023 to 2033 Figure 143: MEA Market Value (US$ Million) by End User, 2023 to 2033 Figure 144: MEA Market Value (US$ Million) by Country, 2023 to 2033 Figure 145: MEA Market Value (US$ Million) Analysis by Country, 2017 to 2033 Figure 146: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 147: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 148: MEA Market Value (US$ Million) Analysis by Disease Indication, 2017 to 2033 Figure 149: MEA Market Value Share (%) and BPS Analysis by Disease Indication, 2023 to 2033 Figure 150: MEA Market Y-o-Y Growth (%) Projections by Disease Indication, 2023 to 2033 Figure 151: MEA Market Value (US$ Million) Analysis by Product Type, 2017 to 2033 Figure 152: MEA Market Value Share (%) and BPS Analysis by Product Type, 2023 to 2033 Figure 153: MEA Market Y-o-Y Growth (%) Projections by Product Type, 2023 to 2033 Figure 154: MEA Market Value (US$ Million) Analysis by End User, 2017 to 2033 Figure 155: MEA Market Value Share (%) and BPS Analysis by End User, 2023 to 2033 Figure 156: MEA Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033 Figure 157: MEA Market Attractiveness by Disease Indication, 2023 to 2033 Figure 158: MEA Market Attractiveness by Product Type, 2023 to 2033 Figure 159: MEA Market Attractiveness by End User, 2023 to 2033 Figure 160: MEA Market Attractiveness by Country, 2023 to 2033
Recommendations
Explore Healthcare Insights
View Reports